This has already led to deterring the release of new drugs into the German market. In the beginning of September, two newly approved drugs were kept from the market as a result of these pricing disincentives. The German company Boehringer Ingelheim and its U.S. partner Eli Lilly recently decided not to launch their new type 2 diabetes drug, Trajenta (linagliptin) in Germany due to the new pricing system. In initial discussions prior to market release, the Federal Joint Committee(G-BA) indicated that Trajenta would not be compared to other gliptins as expected but rather to a generic diabetes drug, in which case it would have to be priced accordingly (press release September 5, 2011)

On September 9, Swiss-based Novartis pulled their new high blood pressure therapeutic, Rasilamlo, from the German market because the company was unable to provide sufficient data for their drug - required as part of the new pricing process. This has created sufficient concern that the new law will be a serious disincentive for approved innovative drugs to be released on the German market. The German Association of Research-Based Pharmaceutical Companies (VFA) has called for fairer pricing rules, but they will most likely be unable to convince the government to revert back to the previous system.